Simon Harford - PAREXEL International CFO, Senior Vice President

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

  President
Mr. Simon Harford was appointed as Chief Financial Officer, Senior Vice President of the Company, effective June 1, 2017. Mr. Harford joins PAREXEL from GlaxoSmithKline plc, where he most recently served as Senior Vice President, Finance, for the company Global Pharmaceuticals business based at GSK global headquarters in Brentford, England. Prior to joining GSK, Mr. Harford served as Group Vice President and Controller for Avon Products, Inc., in New York. Additionally, he spent two decades with Eli Lilly and Company in various finance leadership roles across Europe and in Indianapolis, most notably as Head of Investor Relations and as Vice President and Controller
  President Since 2017  MBA    
781 487-9900  http://www.parexel.com
Harford holds an MBA from the University of Virginia Darden Graduate School of Business

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jeffrey NeedhamPerrigo Company plc
2009
Paul WeningerPerrigo Company plc
2015
Roxanne LaganoZoetis
2015
Ronald JanishPerrigo Company plc
2015
Heidi ChenZoetis
2012
Michael AbermanRegeneron Pharmaceuticals
2015
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Michael StewartPerrigo Company plc
2004
Grainne QuinnPerrigo Company plc
2016
Stefan WeiskopfZoetis
2013
George YancopoulosRegeneron Pharmaceuticals
2016
Jatin ShahPerrigo Company plc
2005
Raghav ChariDr Reddys Laboratories Ltd
2013
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018
John HendricksonPerrigo Company plc
2016
Douglas McCorkleRegeneron Pharmaceuticals
2007
Jing LiSinovac Biotech Ltd
2016
Ian SmithVertex Pharmaceuticals Incorpor
2017
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Clinton LewisZoetis
2018

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

TWTR   
Purchased over 50 shares of
few hours ago
Traded for 1.0
MGTI   
Purchased over 50 shares of
few hours ago
Traded for 1.0
PVCT   
Purchased over 10K shares of
few hours ago
Traded for 1.0
BTSC   
Purchased over 10K shares of
few hours ago
Traded for 1.0
ALNY   
Purchased few shares of
few hours ago
Traded for 1.0
Additionally take a look at Your Equity Center. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.
Search macroaxis.com